Articles tagged with Ebola Virus
The study found that African immigrants experienced discrimination and stigma linked to the Ebola virus, leading to stress and hardships. The researchers emphasize the need for research on infectious diseases affecting immigrant communities in the US.
Experts identify self-disseminating vaccines as a potential solution to control emerging infectious diseases (EIDs) at their animal source. The vaccines use virus-based vectors to deliver vaccinations across populations, making it easier to inoculate animals and prevent disease transmission.
Researchers at Penn University discovered that inhibiting a calcium-signaling pathway can block the Ebola virus from exiting host cells and spreading, paving the way for potential broad-spectrum therapy. This approach has implications for treating multiple serious viral infections, including Marburg, Lassa, and Junin viruses.
A suspected case of sexual Ebola transmission was confirmed using genomic analysis, providing evidence of direct transmission between an EVD survivor and his partner. The study also shows the persistence of infectious EBOV in semen for over 179 days after disease onset.
Researchers estimate that introducing Ebola treatment beds prevented an estimated 57,000 Ebola cases and 40,000 deaths in Sierra Leone. The study suggests that this could have been reduced further if the beds were introduced one month earlier.
A new antiviral compound, GS-5734, has shown 100% survival rate and significant reduction in viral load in infected rhesus monkeys. The compound's ability to block the virus's replication process suggests its potential as a treatment for Ebola virus disease.
The University of Massachusetts Medical School (UMMS) has been awarded a $20 million CDC grant to expand its efforts in preventing another Ebola outbreak in Liberia. The two-year grant will support training of healthcare workers, improvement of public health laboratory systems and hospital diagnostic services.
James Munro of Tufts University School of Medicine has received the NIH Director's New Innovator Award to develop a new way to use single molecule imaging of Ebola glycoproteins. This research aims to inform the design of structure-based vaccines to fight the spread of Ebola.
Recent developments in surveillance technology could enable a swifter response to potentially deadly outbreaks of disease. A team of infectious disease experts found that shortcomings in the global response to Ebola highlight the need for state-of-the-art techniques to detect and monitor outbreaks.
Researchers developed a real-time DNA sequencing test that can detect multiple pathogens, including Ebola, Chikungunya, and hepatitis C, using nanopore sequencing technology. The test can be used in scarce lab environments and provides rapid results, cutting the time required for diagnosis to just minutes.
A team at University of California - Santa Cruz developed chip-based technology for reliable Ebola detection, combining microfluidic and optofluidic chips. The system achieved comparable sensitivity to PCR analysis with excellent specificity.
Genetic mutations in Ebola virus appear to block antibody-based treatments from warding off infection. The mutations, or 'escape variants,' have implications for the continued development of therapeutics to treat Ebola virus disease, which has claimed over 11,000 lives in West Africa.
A new Ebola test using magnetic nanoparticles is 100 times more sensitive than current tests and easier to use, enabling faster isolation of patients and prevention of disease spread. This technology has potential applications in diagnosing other infectious diseases like flu and detecting tumors.
A survey of primary care physicians found significant variation in how doctors make decisions in situations of uncertainty, with those least likely to encounter Ebola patients being most likely to choose overly intense management. The results highlight the need for additional resources and responsible reporting by news media.
A case-series of eight British healthcare workers who received antiviral-based therapies after possible accidental exposure to Ebola virus in Sierra Leone did not develop the disease. The study suggests that post-exposure prophylaxis may be effective in preventing Ebola infection, and authors call for standardised guidelines to be deve...
A team of researchers from Pitt, Drexel, and NIH found that the Ebola virus can survive in detectable concentrations in wastewater for at least a week or longer. The study suggests that procedures for disposing of contaminated liquid waste might underestimate the virus' ability to persist.
The discovery sheds light on how the virus evolved and spread across West Africa, revealing that most cases are caused by spillover infections from wild rodents to humans.
Researchers found that Ebola and Marburg viruses use G protein-coupled receptors to enter cells, which can be blocked by existing drugs targeting these receptors. The study identified 20 GPCR antagonists effective against the two viruses, paving the way for potential therapeutics.
A preclinical study found that a new Ebola vaccine, VSV-EBOV, provides complete protection against the disease when given 7 days before infection in macaques. The vaccine also induces a strong innate immune response, helping to limit virus replication and eventually clearing the virus.
A single dose of the experimental Ebola virus (EBOV) vaccine VSV-EBOV has been shown to completely protect cynomolgus macaques against the current EBOV outbreak strain, EBOV-Makona. The vaccine triggers both innate and adaptive immunity, providing partial protection if given three days prior to exposure.
A proposed global vaccine-development fund could help make vaccines available for emergency use, saving thousands of lives. The fund would cover the financial burden of vaccine development, addressing barriers such as high costs, limited market potential and lack of government support.
A study found that fewer than one in six healthcare workers (4/30) follow CDC guidelines for removing personal protective equipment (PPE). The researchers observed HCWs entering and exiting patient rooms without proper technique, leading to potential pathogen transmission.
The Chicago Ebola Resource Network (CERN) shares expertise, resources, and risk to anticipate and respond to Black Swan events. Collaborative efforts among academic medical centers and public health leaders resulted in efficient programs with reduced disruption to routine patient care.
The Oxford Vaccine Group is conducting a Phase II study of an Ebola vaccine regimen, recruiting over 600 healthy adult volunteers in the UK and France. The study aims to assess the safety and immunogenicity of the vaccine, as well as determine the best timing for each dose.
A clinical trial testing an Ebola vaccine developed on a new cell line is underway in Senegal, aiming to provide a rapid response to outbreaks. The trial uses two vaccines, ChAd3-EBO Z and MVA-EBO Z, which have shown excellent safety profiles and promise for low-cost mass production.
A collaborative team from UTMB and NIH develop an inhalable vaccine that protects primates against Ebola. The aerosol delivery method has shown promising results, with a single vaccination providing protection against the severe disease and death caused by lethal Ebola infection.
The latest Ebola outbreak is the largest, most sustained, and most widespread to date, with several potential treatments undergoing clinical trials. Dr. Ali Mirazimi notes that emerging infectious diseases will continue to challenge global health.
Researchers at Scripps Research Institute identify new immune molecules that protect against deadly Marburg virus, a relative of Ebola virus. The study provides ingredients needed to develop treatments for future Marburg outbreaks.
A new rapid diagnostic test has been shown to accurately diagnose Ebola virus disease within minutes, revolutionizing treatment and containment. The test's sensitivity and specificity rates are comparable to laboratory-based methods, offering a promising solution to the challenges of early diagnosis and timely intervention.
A new study by TSRI researchers provides a higher-resolution view of the Ebola virus life cycle, revealing key vulnerabilities that can be targeted with antiviral therapeutics. The findings also shed light on how the virus assembles its genetic material, which is critical for understanding its structure-based design.
A new point-of-care EVD test has been shown to be faster and as sensitive as a conventional laboratory-based method, detecting the virus in just a small drop of blood. The rapid diagnostic test could help identify case contacts and ultimately curb Ebola's spread by quickly confirming or ruling out cases.
Scientists at the Institut Pasteur sequenced three distinct Ebola virus variants co-circulating in Guinea, with each variant defined by unique mutations affecting viral proteins. The study highlights the genetic diversity of the viruses circulating in Guinea during the epidemic's spread and will aid in optimizing treatments and vaccines.
Engineers at Lehigh University are developing stochastic models to study the dynamics of Ebola virus infection in bats and its potential human transmission. The goal is to quantify the risk associated with the virus's spread and provide a basis for resource allocation and epidemic response strategies.
Researchers report that statins and angiotensin receptor blockers, commonly used for heart disease, can stabilize endothelial cells lining blood vessels in Ebola patients. This approach may improve survival rates in infected individuals by bolstering the immune system.
A global team has sequenced over 200 Ebola virus genomes to capture the fullest picture yet of how the virus is transmitted and changes over time. The study reveals that cross-border transmission played a smaller role in the outbreak than previously thought, and that the virus has begun to weed out mutations that do not benefit it.
A new study in Liberia will investigate the long-term health consequences of Ebola virus disease (EVD) in survivors, determining if they develop immunity that protects them from future infection. The study will also assess whether previously EVD-infected individuals can transmit infection to close contacts and sexual partners.
Researchers found that news media created public panic during the 2014 U.S. Ebola outbreak, with tweets and Google searches peaking in response to news clips. The study used social media data to show how news media manipulated public emotions, highlighting its potential impact on future outbreaks.
A new study by NIH researchers compares the Makona strain of Ebola virus to the original 1976 Mayinga strain, revealing a decreased ability to cause disease in West Africa, with liver damage and rash appearing two days later than in the 1976 strain.
Researchers analyzed over 42,000 Ebola-related tweets to show how Twitter was used to share breaking health news in West Africa. The study found that Twitter played a crucial role in disseminating information about the outbreak, particularly in the days leading up to official announcements.
Researchers have identified Niemann-Pick C1 (NPC1) as a critical protein for the Ebola virus to infect a host, providing a new target for drug development. Blocking NPC1 could lead to effective treatments for this deadly disease.
Scientists discovered the molecular lock of Ebola virus's cellular entry, which could lead to the development of antiviral drugs blocking its interaction with Niemann-Pick C1. The study found mice lacking NPC1 gene were completely resistant to infection, suggesting a potential treatment for Ebola.
A systematic review of published evidence found that extended dual antiplatelet therapy (DAPT) decreases the risk for myocardial infarction but increases major bleeding events and may increase mortality. The authors suggest based on patient preferences after discussing benefits and harms.
Researchers have discovered a promising new treatment for Ebola by screening compounds from existing malaria and flu drugs. The treatment showed a high success rate of up to 90% in treating infected mice with no observable side effects.
A team of researchers, led by Dr. Steve Bellan and including Associate Professor Manoj Gambhir from Monash University, have identified the most effective human trial design for testing Ebola vaccines in Sierra Leone. The study suggests that a modified randomized control trial is the best approach to detect an effective and safe vaccine.
The SAWBO Deployer app allows users to view, download, and share animated educational videos on Android devices, covering topics such as health and agriculture in developing countries. The app enables offline access and sharing through Bluetooth connections, making it an essential tool for outreach workers and community organizations.
A new genomics laboratory in Liberia enables fast tracking of Ebola virus changes, which could impact diagnostics and therapeutics. The lab provides critical viral genomic information to support public health efforts.
FAU researchers have received a NSF Rapid Response Grant to create an innovative model of Ebola spread using big data analytics. The program will use Twitter feeds, Facebook, and Google data to track the spread of the virus and create predictive diffusion models.
The west African Ebola epidemic has sparked interest in global health security, but its impact on political commitment to public health is uncertain. The crisis has highlighted the importance of securing individuals' access to healthcare as part of global health security. Key challenges include counterfeit medicines, antimicrobial resi...
Global health experts offer a new framework for creating a robust global health system with national health systems at its foundation. The framework proposes key priorities, including funding, technical excellence, operational capacities, normative standards, regional offices, and engaging non-state parties.
Researchers solved the structure of Ebola virus nucleoprotein core domain to 1.8 Å resolution, revealing RNA binding groove similarities with other viral NPs. The findings provide valuable insights into EBOV genome assembly and transcription mechanism, as well as potential antiviral therapies targeting RNP formation.
New estimates suggest that the West African Ebola outbreak could have resulted in comparable number of malaria deaths as those due to Ebola itself. Implementing mass drug administration and ITN campaigns may largely mitigate the impact of Ebola on malaria.
A large-scale study of Ebola survivors found persistent health effects, including vision loss, hearing impairment, and cognitive decline. The study highlights the need for strategies to address the long-term health needs of survivors.
Researchers from UTMB and Tekmira Pharmaceuticals have developed a post-exposure treatment effective against a specific strain of Ebola. The treatment uses siRNA to target and neutralize the virus, demonstrating potential benefits beyond improved survival rates.
Researchers are investigating whether plasma from Ebola survivors can help treat patients with the disease. The study aims to determine if protective antibodies in the plasma can be used safely to reduce deaths in current and future outbreaks.
Researchers used TACC's Lonestar4 supercomputer to simulate and analyze data for various vaccine trial designs. They found that a phased-rollout randomized controlled trial would provide better information about the effectiveness of an Ebola vaccine.
A study published in PLOS Medicine proposes a multi-stage approach to testing Ebola treatments, which may be quicker than traditional randomized trials while still providing robust results. This alternative design could potentially triage treatments faster and recommend them without further RCTs under certain circumstances.
Despite significant genetic mutations, Ebola's functional level has remained the same over the past four decades. This suggests that vaccines and treatments developed during current outbreaks may be effective against future outbreaks.
Researchers have found that the Ebola virus uses a protein called VP35 to remove its genetic material's protective coat, allowing it to replicate. Disrupting this process could potentially stop the spread of the disease.
Researchers at UTMB have developed an Ebola vaccine that is both safe and effective with a single dose, providing protection against the deadly virus. The new vaccine employs a 'Trojan horse' approach, using a weakened form of the virus to trigger an immune response.
A new tool uncovers some surprises in diagnosing Ebola by identifying six key symptoms: contact with an infected person, diarrhea, loss of appetite, muscle pain, difficulty swallowing and absence of abdominal pain. This score can help clinicians risk-stratify patients during outbreaks.